BrainStorm gets FDA fast-track status for ALS stem cell therapy
Tuesday, October 7, 2014 - 04:10
in Health & Medicine
TEL AVIV (Reuters) - Israel's BrainStorm Cell Therapeutics said the U.S. Food and Drug Administration has designated its adult stem cell treatment as a "fast-track" product for the treatment of amyotrophic lateral sclerosis (ALS).